US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Monkeypox Concept

1,685.78

-5.8430-0.35%

Number of Gainers:6

Number of Losers:3

Number of Flat:2

PE:- -

High:1,701.25

Open:1,691.93

Low:1,680.58

Close:1,691.62

Volume:23.12M

Turnover:996.69M

Market Cap:187.70B

Float Cap:187.18B

Loading ...

Aethlon Medical Reports Hemopurifier Removes Inflammatory Extracellular Vesicles in Long COVID Study

BUZZ-Bavarian Nordic rises on share buyback - 'positive signal' for investors

Gilead Sciences CEO Daniel O’Day Reports Disposal of Common Shares

Tonix Pharmaceuticals Releases Report on Monoclonal Antibody for Lyme Disease Prevention

Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely?

Simply Wall St.

BRIEF-E-Home to Acquire AI Access Control & Smart Community Firm to Expand Front-End Chain

E-Home Household Service Holdings Acquires Fuzhou Yunding

E-Home Household Services Holdings Limited Decided to Acquire an AI Access Control System and Smart Community Service Company to Expand Its Front-End Industrial Chain

THOMSON REUTERS

Quest Diagnostics Partners with Octave Bioscience to Expand Access to MS Disease Activity Test

What Gilead Sciences (GILD)'s First Lenacapavir Shipments in Africa Mean For Shareholders

Simply Wall St.

Director’s Strategic Stock Sale at Quest Diagnostics!

Quest Diagnostics CEO and President James E. Davis Reports Disposal of Common Shares

Director Vicky B. Gregg Reports Sale of Quest Diagnostics Common Shares

Bid-Ask Spreads on Currencies Narrow as EBS Trade Resumes -- Market Talk

Gilead Sciences (GILD) Gets a Buy from Bernstein

GeoVax Labs Inc. held special shareholder meeting

Vera Therapeutics Appoints James R. Meyers to Board of Directors

Gilead Sciences: Promising Growth and Diversification Beyond HIV with Oncology Expansion

Gilead Sciences Coverage Assumed by Truist Securities at Buy

BRIEF-First Venture Sweden Private Says Sprint Bioscience Sells Cancer Program TREX1 To Gilead Sciences

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4583/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"Monkeypox Concept","latestPrice":1685.7805,"timestamp":1764709199999,"preClose":1691.6235,"halted":0,"volume":23121779,"delay":0,"changeRate":-0.003454,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-5.843018,"latestTime":"12-02 16:00:00 EST","open":1691.9335,"high":1701.25,"low":1680.5822,"amount":996689807.113288,"amplitude":0.012218,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1764723600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.237261,"peRate":36.090635,"turnoverRate":0.008564,"increases":6,"decrements":3,"flats":1,"marketCap":187700986591,"floatMarketCap":187178272808.875},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4583\",,,,,undefined,":{"symbol":"BK4583","high":1701.25,"amplitude":0.012218,"preClose":1691.6235,"low":1680.5822,"pbRate":"4.237261","latestPrice":1685.7805,"volume":23121779,"delay":0,"open":1691.9335,"prevYearClose":1284.7982,"prevWeekClose":1713.9587,"prevMonthClose":1713.9587,"prevQuarterClose":1540.8464,"fiveDayClose":1707.4333,"twentyDayClose":1659.6542,"sixtyDayClose":1583.7096,"secType":"PLATE","market":"US","turnoverRate":0.008564,"peRate":36.090635,"marketCap":187700986591,"floatMarketCap":187178272808.875,"timestamp":1764709199999,"nameCN":"Monkeypox Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4583\",,,,undefined,":{"bkCode":"BK4583","up":6,"down":3,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4583\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2588053472","title":"Aethlon Medical Reports Hemopurifier Removes Inflammatory Extracellular Vesicles in Long COVID Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2588053472","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588053472?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:02","pubTimestamp":1764680572,"startTime":"0","endTime":"0","summary":"Aethlon Medical Inc. has announced the publication of preclinical data demonstrating that the GNA affinity resin in its Hemopurifier device binds to extracellular vesicles  in plasma samples from Long COVID patients and decreases inflammatory microRNAs. The results, published on November 20, 2025, in the pre-print archive bioRxiv, indicate that the Hemopurifier removes both large and small EVs, which are elevated in Long COVID patients compared to recovered controls. Additionally, NanoString analyses identified seven EV-associated microRNAs significantly reduced by treatment with the GNA affinity resin. The company stated that these findings support further investigation of the Hemopurifier in Long COVID. The results from this preclinical study have been submitted for consideration to a peer-reviewed journal and have not yet been presented in a clinical trial context.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT str","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL54kBQw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","AEMD","BK4568","BK4583"],"gpt_icon":0},{"id":"2588037459","title":"BUZZ-Bavarian Nordic rises on share buyback - 'positive signal' for investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2588037459","media":"Reuters","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588037459?lang=en_us&edition=fundamental","pubTime":"2025-12-02 19:41","pubTimestamp":1764675675,"startTime":"0","endTime":"0","summary":"BUZZ-Bavarian Nordic rises on share buyback - 'positive signal' for investors** Bavarian Nordic BAVA.CO shares rise 3.4%, boosted by its DKK 500 mln  buyback plan, which broker Sydbank deems a \"very positive signal\" for investors** The buyback, which overshadows short-term uncertainty, is the board's attempt to mend shareholder relations after the failed takeover bid from Nordic Capital, Permira, Sydbank says as it raises the stock to \"buy\" from \"hold\"** The uncertainty stems from an information meeting planned for Dec. 11 where Bavarian plans to update on the state of the business** Sydbank says the buyback reflects Bavaria's shift from a biotech to a pharma firm, citing acquisitions of travel vaccine portfolios from GSK and Emergent BioSolutions, combined with its core smallpox/mpox business ** The stock is one of the biggest gainers on STOXX 600 .STOXX index","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nL6N3X80MG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EBS","BK4583","BK4139"],"gpt_icon":0},{"id":"2588055997","title":"Gilead Sciences CEO Daniel O’Day Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588055997","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588055997?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:51","pubTimestamp":1764625873,"startTime":"0","endTime":"0","summary":"Daniel Patrick O'Day, Chairman & CEO of Gilead Sciences Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL3Tb2Qz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Gilead Sciences CEO Daniel O’Day Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015952.SGD","BK4566","LU0320765992.SGD","LU0114720955.EUR","LU0289739699.SGD","BK4583","LU1430594728.SGD","LU1778281490.HKD","BK4532","SG9999015986.USD","LU2468319806.SGD","IE00BKVL7J92.USD","LU1066051498.USD","LU0823416689.USD","LU0889565916.HKD","LU1674673428.USD","GILD","IE00B19Z3581.USD","LU1674673691.USD","LU1571399168.USD","LU0882574055.USD","LU0234570918.USD","LU0109394709.USD","LU1585245621.USD","LU2087621335.USD","IE00BZ1G4Q59.USD","BK4588","SG9999015945.SGD","BK4550","SG9999015978.USD","BK4568","IE00BSNM7G36.USD","BK4578","IE00B19Z3B42.SGD","LU1839511570.USD","LU2324357040.USD","IE00B3T34201.USD","LU1066053197.SGD","BK4585","IE0002270589.USD","LU0058720904.USD","IE00B7SZLL34.SGD","BK4139","LU2089984988.USD"],"gpt_icon":0},{"id":"2588266703","title":"Tonix Pharmaceuticals Releases Report on Monoclonal Antibody for Lyme Disease Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2588266703","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588266703?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:35","pubTimestamp":1764624911,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals Holding Corp. published a document discussing a novel monoclonal antibody developed for the prevention of Lyme disease. The document outlines the epidemiology of Lyme disease, current challenges in prevention, and the potential role of monoclonal antibodies as a preventive measure. The full document can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on December 01, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL2KVHQQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TNXP","BK4583","BK4139"],"gpt_icon":0},{"id":"2588709088","title":"Will Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Spend Its Cash Wisely?","url":"https://stock-news.laohu8.com/highlight/detail?id=2588709088","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588709088?lang=en_us&edition=fundamental","pubTime":"2025-12-02 03:39","pubTimestamp":1764617960,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tnxp/tonix-pharmaceuticals-holding/news/will-tonix-pharmaceuticals-holding-nasdaqtnxp-spend-its-cash","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tnxp/tonix-pharmaceuticals-holding/news/will-tonix-pharmaceuticals-holding-nasdaqtnxp-spend-its-cash","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NVIW.SI","NQmain","TSYW.SI","TNXP","MNQmain","PSQ","BK4139","USAW.SI","USJW.SI","QLD",".IXIC","QID","SQQQ","TQQQ","BK4583"],"gpt_icon":1},{"id":"2588777396","title":"BRIEF-E-Home to Acquire AI Access Control & Smart Community Firm to Expand Front-End Chain","url":"https://stock-news.laohu8.com/highlight/detail?id=2588777396","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588777396?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:01","pubTimestamp":1764597668,"startTime":"0","endTime":"0","summary":"BRIEF-E-Home to Acquire AI Access Control & Smart Community Firm to Expand Front-End ChainDec 1 (Reuters) - E-Home Household Service Holdings Ltd EJH.O:E-HOME HOUSEHOLD SERVICES HOLDINGS LIMITED DECID","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA2LXDDZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4192","EJH","BK4539","BK4583"],"gpt_icon":0},{"id":"2588077395","title":"E-Home Household Service Holdings Acquires Fuzhou Yunding","url":"https://stock-news.laohu8.com/highlight/detail?id=2588077395","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588077395?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:01","pubTimestamp":1764597663,"startTime":"0","endTime":"0","summary":"E-Home Household Services Holdings Limited is set to acquire Fuzhou Yunding Mutual Chain Information Technology Co., Ltd., a company specializing in AI access control systems and smart community services. The integration aims to combine E-Home's home service capabilities with Fuzhou Yunding's IoT information platform, enabling end-to-end industry integration and expanding E-Home's presence in the AI and smart community sectors. Fuzhou Yunding currently operates over 500 residential projects in Fujian and Anhui, serving more than 3 million registered users through its mobile app, and collaborates with a range of commercial, public, and governmental entities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. E-Home Household Service Holding","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL9Ht7sK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4583","BK4192","EJH"],"gpt_icon":0},{"id":"2588773689","title":"E-Home Household Services Holdings Limited Decided to Acquire an AI Access Control System and Smart Community Service Company to Expand Its Front-End Industrial Chain","url":"https://stock-news.laohu8.com/highlight/detail?id=2588773689","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588773689?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:00","pubTimestamp":1764597601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA2LXDDZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4192","BK4583","EJH"],"gpt_icon":0},{"id":"2588778502","title":"Quest Diagnostics Partners with Octave Bioscience to Expand Access to MS Disease Activity Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2588778502","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588778502?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:30","pubTimestamp":1764595854,"startTime":"0","endTime":"0","summary":"Quest Diagnostics Incorporated has announced a strategic collaboration with Octave Bioscience to expand patient access to the Octave Multiple Sclerosis Disease Activity  Test across the United States. Through this partnership, patients can utilize Quest's network of approximately 7,000 patient service centers for specimen collection, making the MSDA Test more widely available. The agreement also provides Quest with the first opportunity to offer specimen collection services for future tests developed by Octave for multiple sclerosis and Parkinson's disease. This collaboration aims to enhance the standard of care for neurodegenerative diseases by providing easier access to advanced, blood-based diagnostic tools.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, invest","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL7dh9l5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4588","DGX","LU0950375773.USD","LU2506951958.HKD","LU2506951875.HKD","LU2506952097.USD","BK4585","BK4567","LU0823417737.USD","LU0823417653.USD","LU1854104046.USD","LU2506952170.USD","BK4196","LU1854103824.USD"],"gpt_icon":0},{"id":"2587760721","title":"What Gilead Sciences (GILD)'s First Lenacapavir Shipments in Africa Mean For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2587760721","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587760721?lang=en_us&edition=fundamental","pubTime":"2025-11-30 08:33","pubTimestamp":1764462789,"startTime":"0","endTime":"0","summary":"Gilead Sciences recently delivered its first shipments of the injectable HIV prevention drug lenacapavir to Eswatini and Zambia, advancing efforts to expand access across sub-Saharan Africa.\nThis milestone not only accelerates the availability of long-acting HIV prevention in countries with the highest disease burden but also highlights Gilead's approach of collaborating with governments and generic manufacturers to ensure sustainable and affordable supply.\nWe'll examine how Gilead's move to...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/29002-main-header/1756252861953","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/29002-main-header/1756252861953"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/what-gilead-sciences-gilds-first-lenacapavir-shipments-in-af","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gild/gilead-sciences/news/what-gilead-sciences-gilds-first-lenacapavir-shipments-in-af","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE0002270589.USD","LU0234570918.USD","BK4550","LU0058720904.USD","BK4583","IE00B19Z3B42.SGD","LU1778281490.HKD","LU2468319806.SGD","BK4566","LU1571399168.USD","GILD","BK4532","SG9999015978.USD","LU1585245621.USD","IE00BSNM7G36.USD","IE00B7SZLL34.SGD","LU0889565916.HKD","BK4139","LU1066053197.SGD","LU2324357040.USD","IE00B19Z3581.USD","LU1674673691.USD","LU1839511570.USD","BK4585","LU0823416689.USD","BK4578","LU1430594728.SGD","SG9999015986.USD","LU0882574055.USD","LU2089984988.USD","LU0109394709.USD","LU1674673428.USD","BK4568","IE00BZ1G4Q59.USD","BK4588","LU1066051498.USD","LU2087621335.USD","LU0289739699.SGD","SG9999015945.SGD","SG9999015952.SGD","LU0114720955.EUR","IE00BKVL7J92.USD","LU0320765992.SGD","IE00B3T34201.USD"],"gpt_icon":0},{"id":"2587756731","title":"Director’s Strategic Stock Sale at Quest Diagnostics!","url":"https://stock-news.laohu8.com/highlight/detail?id=2587756731","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587756731?lang=en_us&edition=fundamental","pubTime":"2025-11-29 10:03","pubTimestamp":1764381809,"startTime":"0","endTime":"0","summary":"New insider activity at Quest Diagnostics ( ($DGX) ) has taken place on November 28, 2025. Director Vicky Gregg has recently sold 1,250 shares of Q...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/directors-strategic-stock-sale-at-quest-diagnostics-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/directors-strategic-stock-sale-at-quest-diagnostics-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2506952097.USD","LU0823417737.USD","LU1854103824.USD","BK4567","BK4196","BK4585","DGX","LU0823417653.USD","LU2506951958.HKD","LU0950375773.USD","LU1854104046.USD","LU2506951875.HKD","BK4588","BK4583","LU2506952170.USD"],"gpt_icon":0},{"id":"2587730812","title":"Quest Diagnostics CEO and President James E. Davis Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2587730812","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587730812?lang=en_us&edition=fundamental","pubTime":"2025-11-29 05:32","pubTimestamp":1764365539,"startTime":"0","endTime":"0","summary":"James E. Davis, CEO and President of Quest Diagnostics Incorporated, reported a disposal of common shares of Quest Diagnostics Incorporated. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quest Diagnostics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 28, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL74PKSX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823417737.USD","LU2506952170.USD","LU2506951958.HKD","BK4588","BK4585","BK4567","LU0823417653.USD","LU2506952097.USD","LU2506951875.HKD","LU0950375773.USD","DGX","BK4583","LU1854104046.USD","LU1854103824.USD","BK4196"],"gpt_icon":0},{"id":"2587308147","title":"Director Vicky B. Gregg Reports Sale of Quest Diagnostics Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2587308147","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587308147?lang=en_us&edition=fundamental","pubTime":"2025-11-29 05:31","pubTimestamp":1764365467,"startTime":"0","endTime":"0","summary":"Vicky B. Gregg, Director of Quest Diagnostics Incorporated, has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quest Diagnostics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL730BML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Director Vicky B. Gregg Reports Sale of Quest Diagnostics Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4196","BK4588","LU1854103824.USD","BK4567","LU0823417653.USD","LU2506952097.USD","LU0950375773.USD","LU2506951958.HKD","LU2506951875.HKD","LU0823417737.USD","DGX","BK4585","LU2506952170.USD","LU1854104046.USD"],"gpt_icon":0},{"id":"2586878276","title":"Bid-Ask Spreads on Currencies Narrow as EBS Trade Resumes -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2586878276","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586878276?lang=en_us&edition=fundamental","pubTime":"2025-11-28 20:58","pubTimestamp":1764334680,"startTime":"0","endTime":"0","summary":"1258 GMT - Spreads between the bid and ask rates in currencies have come down after the Chicago Mercantile Exchange confirmed that the EBS market forex platform had reopened after an outage. EBS, which makes up a significant proportion of forex trades, was affected by Friday's outage at the CME. Spreads in the euro against the dollar last showed a bid rate of $1.1569 and an ask rate very close to that, at $1.1570. The main impact of the EBS outage had been wider spreads, as well as poorer market liquidity, ING's Chris Turner says. Other areas of CME trading remain down, however, including those for futures and options, and continue to affect financial markets. The CME cited a cooling problem at a data-center provider. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"86e3784809e736247981e9bf51071b14","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823417737.USD","LU0823417653.USD","LU1732800096.USD","LU1732799900.SGD","LU1599440770.SGD","LU2506951875.HKD","BK4566","EBS","LU2237438978.USD","IE0004091025.USD","IE00BDGV0183.EUR","LU0545562505.USD","LU0731783048.USD","LU0158827948.USD","IE00B42XCP33.USD","LU0265550359.USD","LU1228905037.USD","LU2506952097.USD","LU2506952170.USD","LU1509826696.USD","BK4139","IE00BGHQF631.EUR","IE00B3T34201.USD","LU0795875169.SGD","LU1116320737.USD","LU1481011911.USD","LU1116320901.HKD","IE0004086264.USD","LU1481011671.HKD","LU0912757837.SGD","IE000M9KFDE8.USD","LU0795875086.SGD","BK4585","CME","BK4561","LU0234570918.USD","LU1228905540.USD","LU0070217475.USD","LU0731783394.SGD","LU2506951958.HKD","IE00B3PB1722.GBP","BK4583","LU2023251221.USD","LU2347655156.SGD","LU2089283258.USD","LU2089284900.SGD","LU0742537680.HKD","LU0950375773.USD","LU0772969993.USD","IE00BVYPNV92.GBP"],"gpt_icon":0},{"id":"2586037362","title":"Gilead Sciences (GILD) Gets a Buy from Bernstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2586037362","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586037362?lang=en_us&edition=fundamental","pubTime":"2025-11-28 13:35","pubTimestamp":1764308120,"startTime":"0","endTime":"0","summary":"In a report released on November 26, Courtney Breen from Bernstein maintained a Buy rating on Gilead Sciences, with a price target of $135.00. The ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/gilead-sciences-gild-gets-a-buy-from-bernstein-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/gilead-sciences-gild-gets-a-buy-from-bernstein-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0823416689.USD","IE00B19Z3581.USD","IE00B3T34201.USD","LU1066051498.USD","LU2324357040.USD","SG9999015978.USD","LU0889565916.HKD","BK4578","BK4139","LU1674673691.USD","BK4588","GILD","IE00B19Z3B42.SGD","BK4550","SG9999015952.SGD","LU0234570918.USD","BK4583","BK4566","LU1674673428.USD","LU2089984988.USD","BK4532","LU0114720955.EUR","IE00BKVL7J92.USD","LU0109394709.USD","LU1066053197.SGD","LU2087621335.USD","BK4568","LU1430594728.SGD","LU1585245621.USD","LU2468319806.SGD","LU1571399168.USD","LU0882574055.USD","LU0058720904.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","SG9999015945.SGD","SG9999015986.USD","LU0289739699.SGD","LU1778281490.HKD","IE0002270589.USD","LU1839511570.USD","LU0320765992.SGD","IE00B7SZLL34.SGD","BK4585"],"gpt_icon":0},{"id":"2586426090","title":"GeoVax Labs Inc. held special shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2586426090","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586426090?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:06","pubTimestamp":1764191212,"startTime":"0","endTime":"0","summary":"GeoVax Labs Inc. held a special meeting of stockholders on November 26, 2025. Stockholders approved the issuance of up to 11,904,768 shares of common stock upon exercise of warrants issued in connection with a private placement offering. Stockholders also approved an amendment to the Certificate of Incorporation to effect a reverse stock split of the issued and outstanding common stock at a ratio between 1-for-10 and 1-for-25, with the exact ratio to be determined by the Board of Directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GeoVax Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Com","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL671F1f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4583","GOVX"],"gpt_icon":0},{"id":"2586260928","title":"Vera Therapeutics Appoints James R. Meyers to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2586260928","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586260928?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:05","pubTimestamp":1764191116,"startTime":"0","endTime":"0","summary":"Vera Therapeutics Inc. has appointed James R. Meyers, a veteran biopharmaceutical executive with extensive commercial leadership experience, to its Board of Directors. Meyers previously held key roles at Gilead Sciences and IntraBio Ltd., and currently serves on the boards of Sangamo Therapeutics, Inc. and CytomX Therapeutics, Inc.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on November 26, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL4zD5dP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B64PRP62.GBP","LU1571399168.USD","BK4112","BK4539","IE00B19Z3B42.SGD","LU2324357040.USD","IE00BKVL7J92.USD","LU1066053197.SGD","BK4578","IE00B19Z3581.USD","SG9999015986.USD","IE00BGHQF748.EUR","LU2210149790.SGD","LU0889565916.HKD","LU1430594728.SGD","BK4585","LU2210150020.SGD","NDAQ","LU0109394709.USD","LU0058720904.USD","VERA","BK4566","SG9999015978.USD","LU2087621335.USD","IE00BSNM7G36.USD","LU0114720955.EUR","SG9999015945.SGD","IE0002270589.USD","LU1585245621.USD","BK4139","LU1778281490.HKD","CTMX","LU1066051498.USD","LU2089984988.USD","IE00B3QW5Z07.USD","BK4583","BK4550","GILD","LU0289739699.SGD","BK4568","LU1674673691.USD","LU2095319765.USD","LU1674673428.USD","LU0823416689.USD","LU0320765992.SGD","SGMO","BK4556","IE00BZ1G4Q59.USD","LU1839511570.USD"],"gpt_icon":0},{"id":"2586902464","title":"Gilead Sciences: Promising Growth and Diversification Beyond HIV with Oncology Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2586902464","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586902464?lang=en_us&edition=fundamental","pubTime":"2025-11-25 05:05","pubTimestamp":1764018336,"startTime":"0","endTime":"0","summary":"BMO Capital analyst Evan Seigerman maintained a Buy rating on Gilead Sciences today and set a price target of $135.00. Evan Seigerman has given his...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/gilead-sciences-promising-growth-and-diversification-beyond-hiv-with-oncology-expansion-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/gilead-sciences-promising-growth-and-diversification-beyond-hiv-with-oncology-expansion-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1571399168.USD","LU1066053197.SGD","SG9999015978.USD","BK4532","BK4585","LU0882574055.USD","LU1430594728.SGD","LU0889565916.HKD","BK4568","LU1674673691.USD","BK4139","BK4550","IE00BSNM7G36.USD","LU2087621335.USD","GILD","LU2324357040.USD","BK4578","SG9999015952.SGD","IE00B7SZLL34.SGD","SG9999015986.USD","IE00BKVL7J92.USD","LU2468319806.SGD","LU0058720904.USD","LU1585245621.USD","IE0002270589.USD","LU2089984988.USD","LU0234570918.USD","SG9999015945.SGD","BK4588","BK4583","IE00B19Z3B42.SGD","IE00BZ1G4Q59.USD","LU0114720955.EUR","LU1066051498.USD","LU0320765992.SGD","IE00B19Z3581.USD","IE00B3T34201.USD","LU1674673428.USD","LU0289739699.SGD","LU0823416689.USD","LU0109394709.USD","BK4566","LU1839511570.USD","LU1778281490.HKD"],"gpt_icon":0},{"id":"2586649438","title":"Gilead Sciences Coverage Assumed by Truist Securities at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2586649438","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586649438?lang=en_us&edition=fundamental","pubTime":"2025-11-25 02:21","pubTimestamp":1764008460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GILD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 24, 2025 13:21 ET (18:21 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1674673428.USD","IE0002270589.USD","SG9999015986.USD","BK4139","LU0114720955.EUR","GILD","BK4588","LU0882574055.USD","LU1430594728.SGD","LU1585245621.USD","LU1066053197.SGD","SG9999015978.USD","BK4550","LU1571399168.USD","IE00B3T34201.USD","LU0109394709.USD","LU1066051498.USD","LU2087621335.USD","BK4532","BK4585","IE00B7SZLL34.SGD","BK4568","LU0289739699.SGD","IE00BSNM7G36.USD","LU0823416689.USD","LU0889565916.HKD","IE00BZ1G4Q59.USD","LU2089984988.USD","SG9999015945.SGD","BK4583","LU1839511570.USD","IE00B19Z3B42.SGD","LU0234570918.USD","LU0058720904.USD","LU1674673691.USD","IE00BKVL7J92.USD","LU0320765992.SGD","LU2468319806.SGD","BK4578","IE00B19Z3581.USD","LU1778281490.HKD","BK4566","SG9999015952.SGD","LU2324357040.USD"],"gpt_icon":0},{"id":"2585890495","title":"BRIEF-First Venture Sweden Private Says Sprint Bioscience Sells Cancer Program TREX1 To Gilead Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2585890495","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585890495?lang=en_us&edition=fundamental","pubTime":"2025-11-24 23:19","pubTimestamp":1763997561,"startTime":"0","endTime":"0","summary":"BRIEF-First Venture Sweden Private Says Sprint Bioscience Sells Cancer Program TREX1 To Gilead SciencesNov 24 (Reuters) - First Venture Sweden Private AB FIRSTb.ST:SPRINT BIOSCIENCE SELLS CANCER PROGR","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nFWN3X00JR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BRIEF-First Venture Sweden Private Says Sprint Bioscience Sells Cancer Program TREX1 To Gilead Sciences","news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD","SG9999015945.SGD","BK4568","LU0058720904.USD","IE0002270589.USD","LU0823416689.USD","LU0234570918.USD","LU0889565916.HKD","LU0289739699.SGD","LU1585245621.USD","BK4550","LU0320765992.SGD","LU1430594728.SGD","LU1778281490.HKD","LU2468319806.SGD","SG9999015978.USD","IE00BSNM7G36.USD","LU0882574055.USD","SG9999015986.USD","BK4566","LU0114720955.EUR","BK4532","LU1066051498.USD","BK4583","LU1066053197.SGD","SG9999015952.SGD","LU1839511570.USD","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","LU1571399168.USD","LU2089984988.USD","LU1674673691.USD","IE00B3T34201.USD","LU2087621335.USD","BK4585","IE00BZ1G4Q59.USD","IE00B19Z3B42.SGD","BK4139","BK4588","LU1674673428.USD","LU2324357040.USD","BK4578","LU0109394709.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":56,"code":"91000000","status":"200"}]}}